MMRF Ranked in Top One Percent of Nonprofits for Exceptional Management of Donors’ Funds. The Multiple Myeloma Research Foundation (MMRF) announced today that Charity Navigator, America’s premier independent evaluator of charitable organizations, has awarded the MMRF with its 4-star rating, the highest rating possible, for the ninth consecutive year – demonstrating exceptional fiscal responsibility in the MMRF’s efforts to bring patients the next generation of treatments and find a cure for multiple myeloma.
This distinguished recognition is an honor that only one percent of charities nationwide have earned. Charity Navigator’s 4-star rating is conferred only to nonprofits that exceed industry standards and regularly outperform other charities. This outstanding ranking not only differentiates the MMRF from its peers but also demonstrates to the public that the MMRF is worthy of their trust and investment.
In 2011, Charity Navigator launched a new, two-dimensional rating system that measures each charity’s Financial Health and Accountability & Transparency. As a result of the new scoring system, 19% of the 5,500 ranked charities’ star ratings decreased. The MMRF is proud to have maintained its elite 4-star ranking – demonstrating exceptional fiscal efficiency given the increasingly discerning rating system.
“Charity Navigator’s 4-star rating underscores our tireless commitment to donor accountability and measurable results,” said Walter M. Capone, Chief Operating Officer of the MMRF. “Every donation expands the portfolio of promising therapies, accelerates their development, and enhances their access to extend patients’ lives through our innovative collaborations with outstanding research institutions and industry partners. Together we are now building toward personally targeted treatments in pursuit of potentially curative approaches for multiple myeloma.”
In addition to receiving the 4-star rating from Charity Navigator, the MMRF has received a “Best in America” Seal of Excellence from the Independent Charities of America, and an A rating from the American Institute of Philanthropy. The MMRF is recognized by Philanthropedia as one of 16 expert-identified, high-impact nonprofits in the field of cancer and continues to fulfill all of the Better Business Bureau’s (BBB) Wise Giving Alliance Standards for Charity Accountability. The MMRF has also received approval from the National Cancer Institute for its research grants program.
About the Multiple Myeloma Research Foundation (MMRF)
Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy’s diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world’s number-one private funder of multiple myeloma research, the MMRF has raised over $190 million since its inception to fund nearly 120 laboratories worldwide, including 70 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated more than 35 clinical trials through its affiliate organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donors’ investments, the MMRF has been consistently recognized for its sound fiscal management. For more information about the MMRF, please visit www.themmrf.org.
- The Multiple Myeloma Research Foundation Creates TrialX Powered Patient Navigator Program to Help Patients!
- MMRF Patient Navigator Available to Help Multiple Myeloma Patients Find Clinical Trials
- Multiple Myeloma Research Foundation (MMRF) and Astellas Pharma Global Development Enter Joint Collaboration to Accelerate Multiple Myeloma Drug Development
- Multiple Myeloma Research Foundation (MMRF) Honors Firefighters at Tri-State 5K Walk/Run to Raise Funds for Cancer Research
- The Multiple Myeloma Research Foundation and Onyx Pharmaceuticals – Dedicated to better treatments for Multiple Myeloma